LENZ Therapeutics CFO receives 652,063 stock options

Four equal 25% vesting tranches depend on the reporting person's service as Interim President and CEO through each applicable date.

Available on EDGAR 11/03/2026 - 07:27 PM EST Accepted by SEC EDGAR 11/03/2026 - 07:26 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

LENZ Therapeutics, Inc. Chief Financial Officer Daniel R. Chevallard acquired a stock-option award covering 652,063 common shares on October 30, 2026, with a $3.05 exercise price and an October 29, 2036 expiration date. Subject to his serving as the issuer’s Interim President and CEO through each applicable date, the options vest in four equal 25% tranches.

Insider Trade Summary

Grant/Award: 652,063 shares

Grant/Award 1 txn

Insider Chevallard Daniel R.

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	652,063	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 652,063 contracts (Direct)

Holdings Before and After: Stock Option (right to buy), 0 to 652,063 contracts (Direct)

Footnotes (1)

1. F1. Subject to the Reporting Person serving as the Issuer's Interim President and CEO through each applicable date, the shares subject to the option shall vest in four equal tranches, as follows: 25% of the shares subject to the option shall commence vesting on November 1, 2026 and vest in full on November 1, 2027; 25% of the shares subject to the option shall commence vesting on February 1, 2027 and vest in full on February 1, 2028; 25% of the shares subject to the option shall commence vesting on May 1, 2027 and vest in full on May 1, 2028; 25% of the shares subject to the option shall commence vesting on August 1, 2027 and vest in full on August 1, 2028. If the Reporting Person ceases to serve as the Issuer's Interim President and CEO for any reason, any tranche for which the vesting commencement date has not yet occurred will be forfeited, and any tranche for which the vesting commencement date has occurred will remain eligible to vest.

Key Figures

Options awarded: 652,063 options Exercise price: $3.05 per share Expiration date: October 29, 2036 +1 more

4 metrics

Options awarded 652,063 options Stock-option award dated October 30, 2026

Exercise price $3.05 per share Stock-option award

Expiration date October 29, 2036 Stock-option award

Vesting schedule Four equal 25% tranches Subject to serving as the issuer’s Interim President and CEO through each applicable date

Key Terms

Stock Option, exercise price, vesting commencement date

3 terms

Stock Option financial

"Stock Option (right to buy)"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise price financial

"conversion_or_exercise_price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting commencement date financial

"the vesting commencement date has not yet occurred"

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When do Daniel R. Chevallard’s LENZ options vest?

The options vest in four equal 25% tranches, subject to Daniel R. Chevallard serving as LENZ’s Interim President and CEO through each applicable date. The tranches commence vesting on November 1, 2026, February 1, 2027, May 1, 2027 and August 1, 2027, and vest in full on November 1, 2027, February 1, 2028, May 1, 2028 and August 1, 2028, respectively.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chevallard Daniel R.

(Last) (First) (Middle)

C/O LENZ THERAPEUTICS, INC.

201 LOMAS SANTA FE DRIVE, SUITE 300

(Street)

SOLANA BEACH CALIFORNIA 92075

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LENZ Therapeutics, Inc. [ LENZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$3.05	10/30/2026		A		652,063		(1)	10/29/2036	Common Stock	652,063	$0	652,063	D

Explanation of Responses:

1. Subject to the Reporting Person serving as the Issuer's Interim President and CEO through each applicable date, the shares subject to the option shall vest in four equal tranches, as follows: 25% of the shares subject to the option shall commence vesting on November 1, 2026 and vest in full on November 1, 2027; 25% of the shares subject to the option shall commence vesting on February 1, 2027 and vest in full on February 1, 2028; 25% of the shares subject to the option shall commence vesting on May 1, 2027 and vest in full on May 1, 2028; 25% of the shares subject to the option shall commence vesting on August 1, 2027 and vest in full on August 1, 2028. If the Reporting Person ceases to serve as the Issuer's Interim President and CEO for any reason, any tranche for which the vesting commencement date has not yet occurred will be forfeited, and any tranche for which the vesting commencement date has occurred will remain eligible to vest.

Remarks:

	/s/ Evert Schimmelpennink, as Attorney-in-Fact	11/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)